Ge Healthcare Bio-sciences Ab

Cytiva Bioprocess R&d Ab

Cytiva Sweden Ab

Ge Healthcare Bioprocess R&d Ab

Ge Healthcare Bioprocess R&d

Martin Hall

Gustav Jose Rodrigo

Jinyu Zou

Per-Mikael Aberg

Sture Larsson

Andreas Muranyi

Jean-Luc Maloisel

Karol Lacki

Helena Skoglar

Karolina Busson

James Van Alstine

Nils Stafstrom

Rolf Hjorth

Jamil Shanagar

Gunnar Malmquist

Camilla Estmer Nilsson

Ida Eklind

Sandeep Kristiansson

Mattias Bryntesson

Mikael Berg

Per-Mikael ÅBerg

The present invention relates to a chromatography ligand, which comprises Domain C fromprotein A (SpA), or a functional fragment or variant thereof. The chromatography ligand presents an advantageous capability of withstanding harsh cleaning in place (CIP) conditions, and is capable of binding Fab fragments of antibodies. The ligand may be provided with a terminal coupling group, such as arginine or cysteine, to facilitate its coupling to an insoluble carrier such as beads or a membrane. The invention also relates to a process of using the ligand in isolation of antibodies, and to a purification protocol which may include washing steps and/or regeneration with alkali.

Chromatography ligand comprising domain c fromprotein a for antibody isolation

The present invention relates to the field of chromatography. More closely, the invention relates to a chromatographic method for purification of proteins, such as Factor VIII, von Willebrand factor and Factor IX. The chromatographic method is performed on a matrix comprising an inner porous core and outer porous lid surrounding said core.

Chromatographic methods for purification of proteins from plasma

The present invention relates to the field of chromatography. More closely, the invention relates to a chromatographic method for purification of plasmaproteins, such as Factor VIII, von Willebrand factor and Factor IX. The chromatographic method is performed on a matrix comprising an inner porous core and outer porous lid surrounding said core.

The present invention relates to a chromatography ligand, which comprises Domain C fromprotein A (SpA), or a functional fragment or variant thereof. The chromatography ligand presents an advantageous capability of withstanding harsh cleaning in place (CIF) conditions, and is capable of binding Fab fragments of antibodies. The ligand may be provided with a terminal coupling group, such as arginine or cysteine, to facilitate its coupling to an insoluble carrier such as beads or a membrane. The invention also relates process of using the ligand in isolation of antibodies, and to a purification protocol which may include washing steps and/or regeneration with alkali.

Chromatography ligand comprising domain C fromprotein A for antibody isolation

The present invention relates to the field of chromatography. More closely, the invention relates to a chromatographic method for purification of Factor VIII and von Willebrand factor from a cryoprecipitate of plasma. The chromatographic method is performed on a matrix comprising an inner porous core and outer porous lid surrounding said core.

Method for chromatography

A chromatography system for separation of a biopolymer is described, comprising at least one feed tank, at least one hold tank, at least one elution buffer tank, at least one eluate tank, at least two packed bed chromatography columns and at least one pump and at least one outlet detector both fluidically connected to said each packed bed chromatography column, wherein the feed tank, the hold tank(s), the elution buffer tank and the eluate tank are each fluidically connected to the packed bed chromatography columns via a system of valves.

System and process for biopolymer chromatography

The invention discloses a method for correcting a baseline in a chromatogram obtained using a buffer with at least one UV-absorbing component which is a weak acid or a weak base. The method comprises the steps of: a) providing a chromatography system with a chromatography column and a UV detector downstream of the chromatography column; b) providing UV extinction coefficients at a wavelength &#x3bb; for the acid form and the base form of the UV-absorbing component(s) and a dissociation constant for the component(s), c) obtaining a chromatogram with the UV detector at wavelength &#x3bb; using the buffer under a set of conditions where pH and/or conductivity is varied between these conditions, d) for a plurality of said conditions calculating the concentrations of the acid and base forms using the dissociation constant(s) and values for pH and conductivity values, and e) calculating UV absorption values of the acid and base forms from the concentrations and UV extinction coefficients under the conditions in question and subtracting the UV absorption values from the chromatogram.

Method for baseline correction in a chromatogram

The present invention relates to a chromatography ligand, which comprises Domain C fromprotein A (SpA), or a functional fragment or variant thereof. The chromatography ligand presents an advantageous capability of withstanding harsh cleaning in place (CIP) conditions, and is capable of binding Fab fragments of antibodies. The ligand may be provided with a terminal coupling group, such as arginine or cysteine, to facilitate its coupling to an insoluble carrier such as beads or a membrane. The invention also relates process of using the ligand in isolation of antibodies, and to a purification protocol which may include washing steps and/or regeneration with alkali.

[object Object]

The present invention relates to a process of enriching one target compound from a liquid, which process comprises at least one step of isolation performed by differentially partitioning between two aqueous phases. In the present invention the phases are formed by adding a thermally responsive, self-associating (i.e. clouding) hydrophilic polymer, and if needed some additional salts, to an aqueous biotechnical solution (such as a fermentation sample or bioseparation process stream) under thermal and other conditions where the solution separates into a one polymer, two-phase system with one phase enriched in the polymer. The target compound is to be found in the phase not enriched in the polymer, while a significant though varying percentage of contaminants may differentially partition to the phase interface or the polymer enriched phase. With minor or no modification the target containing phase solution can be further processed via standard unit operations such as precipitation, chromatography, and filtration to further purify target and remove any residual polymer.

Growing community of inventors

Uppsala, Sweden

Martin Hall